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ABSTRACT The Epstein–Barr virus (EBV) encoded nu-
clear antigen (EBNA) 1 is expressed in latently infected B
lymphocytes that persist for life in healthy virus carriers and
is the only viral protein regularly detected in all EBV associ-
ated malignancies. The Gly-Ala repeat domain of EBNA1 was
shown to inhibit in cis the presentation of major histocom-
patibility complex (MHC) class I restricted cytotoxic T cell
epitopes from EBNA4. It appears that the majority of antigens
presented via the MHC I pathway are subject to ATP-
dependent ubiquitination and degradation by the proteasome.
We have investigated the inf luence of the repeat on this
process by comparing the degradation of EBNA1, EBNA4, and
Gly-Ala containing EBNA4 chimeras in a cell-free system.
EBNA4 was efficiently degraded in an ATPyubiquitiny
proteasome-dependent fashion whereas EBNA1 was resistant
to degradation. Processing of EBNA1 was restored by deletion
of the Gly-Ala domain whereas insertion of Gly-Ala repeats of
various lengths and in different positions prevented the
degradation of EBNA4 without appreciable effect on ubiquiti-
nation. Inhibition was also achieved by insertion of a Pro-Ala
coding sequence. The results suggest that the repeat may affect
MHC I restricted responses by inhibiting antigen processing
via the ubiquitinyproteasome pathway. The presence of reg-
ularly interspersed Ala residues appears to be important for
the effect.
The Epstein–Barr virus (EBV) nuclear antigen (EBNA) 1 is
the only viral protein regularly detected in all EBV-associated
malignancies and is likely to be expressed also in latently
infected B lymphocytes that serve as the viral reservoir in
healthy virus carriers (reviewed in ref. 1). Several lines of
evidence suggest that EBNA1 may be exempted from the
efficient major histocompatibility complex (MHC) class I-
restricted cytotoxic T lymphocyte (CTL)-mediated surveil-
lance that prevents the uncontrolled proliferation of EBV-
transformed blasts. Thus, EBNA1-expressing cells are not
recognized by EBV-specific CTLs isolated from blood during
acute primary infections (2) or by effectors reactivated by
stimulation of lymphocytes from healthy EBV carriers with
autologous virus infected cells (3, 4). Furthermore, expression
of EBNA1 did not confer immunogenicity to transfected
murine mammary carcinoma cells whereas immunogenicity
was induced by expression of other EBV proteins that are
highly immunogenic in humans, suggesting that CTL evasion
may occur across species (5).
Previous evidence has implicated the internal Gly-Ala re-
peat domain of EBNA1 as a cis-acting inhibitor of MHC class
I-restricted presentation (6). Insertion of the domain down-
stream of the immunodominant human leukocyte antigen
(HLA) A11 restricted epitope in EBNA4 was shown to prevent
recognition of the chimeric protein by EBV-specific CTLs.
Conversely, the epitope was presented in the context of an
EBNA1 deletion mutant lacking the Gly-Ala repeat but not in
the context of the native, Gly-Ala containing protein. Two
possible mechanisms may explain this effect. Presence of the
repeat may interfere with the proteolytic machinery that leads
to the production of antigenic peptides. Alternatively, Gly-Ala
containing proteins may be sequestered in cellular compart-
ments that are not accessible to the appropriate type of
processing.
An increasing body of evidence implicates the ubiquitiny
proteasome-dependent protein degradation system in the pro-
duction of peptides for MHC class I-restricted presentation (7,
8). Treatment with peptide aldehydes that inhibit the major
peptidase activity of the 20S subunit was shown to prevent the
degradation of ubiquitinated proteins by the 26S proteasome
(9). Cells treated with the proteasome specific inhibitor,
lactacystin, failed to present influenza nucleoprotein to spe-
cific CTLs but retained the capacity to present defined
epitopes expressed as cytosolic peptides by recombinant vac-
cinia viruses (10). Targeting of this protein degradation path-
way by the Gly-Ala repeat could provide an efficient means to
selectively hamper MHC class I-restricted responses. We have
tested this possibility by comparing the capacity of native and
Gly-Ala containing EBNA4 to act as substrate for ubiquitiny
proteasome-dependent degradation in in vitro processing as-
says.
MATERIALS AND METHODS
Reagents. Phenylhydrazine, ubiquitin, ATP, phosphokreat-
ine, and creatine phosphokinase were purchased from Sigma.
Hexokinase was purchased from Boehringer Mannheim. The
proteasome inhibitor carbobenzoxy-L-leucil-L-leucil-L-
leucinal (MG 132) was obtained from Peptides International.
Ubiquitin aldehyde was prepared as described (11).
Plasmids. Plasmids containing the EBNA1 gene from the
B95.8 virus (pBS-E1) and an EBNA1 deletion mutant lacking
the Gly-Ala repeat (pBS-E1DGA) were described (6). An
EBNA4 cDNA was amplified by reverse transcription–PCR
using the primers 59-GCGGATCCATAATGAAGAAA-
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GCGTGGCTC-39 and 59-ATGAATTCTCACTCATCGTTC-
GATGTT-39. The PCR product was cloned in the pBS-
KS(1)II vector (Stratagene) and sequenced using terminal
and internal primers. The full-length Gly-Ala domain of the
B95.8 EBNA1 (flGA, coordinates 108,201–108,930) was sub-
cloned into the SmaI site of the pBS-KS(1)II vector, and the
E4-flGA chimera was obtained by inserting the cassette in the
MscI site of EBNA4. Insertion in reverse orientation yielded
a chimera encoding a Pro-Ala repeat, E4-PPA. A short
Gly-Ala fragment with unique EBNA1 flanking sequences was
obtained by low stringency PCR amplification using the prim-
ers 59-ATGGATCCACGTCCATTGCATTGGCTGCA-39
and 59-GCGAATTCCTGGCTCTTTCACGTCCTCTAC-39.
The PCR products were cloned in the BamHIyEcoRI sites of
the pGEX2TK plasmid (Pharmacia), and recombinants with
in-frame insertions were identified by Western blot analysis
using Gly-Ala-specific reagents (12). The GA39 cassette was
constructed by recloning the insert in the BamHIyEcoRI sites
of pBS-KS(1)II, and the coding capacity was confirmed by
sequencing. Insertion of the cassette in the SspI and MscI sites
of EBNA4 yielded the E4-GA39(S) and E4-GA39(M) chime-
ras that contain a 17-amino acid-long Gly-Ala repeat. Wild-
type and chimeric genes were subcloned into the pSP64poly(A)
plasmid (Promega), and the constructs were used as templates
for transcriptionytranslation in a coupled reticulocyte system
(TNT; Promega). In vitro-translated proteins were resolved by
SDSyPAGE, transferred onto nitrocellulose, and visualized by
enhanced chemiluminescence (Amersham Life Science) using
the EBNA1-specific mouse mAb OT1x (13), affinity purified
human antibodies specific for the EBNA1 Gly-Ala repeat (12),
and a previously characterized polyclonal human serum con-
taining high titers of antibodies to all EBNAs (6).
In Vitro Processing Assays. Crude rabbit reticulocyte lysates
were prepared as described (14). Reticulocyte rich blood was
obtained from 3-week-old phenylhydrazine-treated female
rabbits. Endogenous ubiquitinyprotein conjugates were dis-
rupted by incubation for 2 hr at 37°C in PBS containing 0.2 mM
2,4-dinitrophenol and 20 mM 2-deoxyglucose, and the reticu-
locytes were lysed in 1.5 volumes of 1 mM DTT. Particulate
material was removed by centrifugation at 80,000 3 g for 90
min, and aliquots of the supernatant were snap frozen and
stored at 280°C. For reconstitution assays, the crude lysate
were fractionated by ion exchange chromatography (DE-52,
Whatman) (15). The nonadsorbed material (fraction I) con-
tains haemoglobin, ubiquitin, and several E2 conjugating
enzymes. The adsorbed material (fraction II) contains the
remaining enzymes required for ubiquitin-dependent degra-
dation.
The 35S-labeled proteins were obtained by in vitro transcrip-
tionytranslation in the presence of [35S]methionine (Amer-
sham) and further purified by fractionation on DEAE-
cellulose. One to 2 ml of the labeled substrate (25,000–30,000
cpm) were incubated with 5 ml of the lysate in processing buffer
(40 mM TriszHCl, pH 7.6y5 mM MgCl2y2 mM DTT) contain-
ing ATPyATP regenerating (0.5 mM ATPy10 mM creatine
phosphatey5 mg creatine phosphokinase) or ATP depleting
systems (10 mM 2-deoxyglucosey0.5 mg hexokinase). Protea-
some inhibitors were added where indicated. Protein break-
down was determined according to standard protocols by
trichloroacetic acid (TCA) precipitation after incubation for 2
hr at 37°C or 4°C (14). The precipitates were pelleted for 5 min
at 14.000 3 g, and the radioactivity in the supernatant was
measured in a b-counter (LKB). The percent degradation was
calculated as the ratio between the input radioactivity and the
radioactivity recovered in the supernatants after subtracting
the background of samples incubated at 4°C. The specific
degradation corresponds to the difference between degrada-
tion in the presence or absence of ATP. The specificity of the
reactions was confirmed by SDS-PAGE and densitometry
tracing by PhosphorImager (Molecular Dynamics). The for-
mation of ubiquitinyprotein conjugates was visualized by per-
forming the reaction in the presence of ATP-gS and ubiquitin
aldehyde (11).
Protein Turnover in Vivo. CV1 cells were infected with
recombinant vaccinia viruses expressing EBNA1 or E1-DGA
(6) at m.o.i. 10 for 8 hr, labeled with [35S]methionine-cysteine
mixture for 1 hr, and then chased in medium containing excess
cold methionine and cysteine for the indicated time. Cells (5 3
106) were lysed in 1 ml lysis buffer containing 1% Nonidet
P-40y150 mM NaCly50 mM Tris, pH 7.5y1 mM phenylmeth-
ylsulfonyl f luoride, and the lysates were precleared overnight
with 2 ml normal mouse serum at 4°C. EBNA1 polypeptides
were immunoprecipitated with the OT1x mAb, resolved by
SDSyPAGE, and visualized by PhosphorImager.
RESULTS
Sensitivity of EBNA4 and EBNA1 to UbiquitinyProteasome-
Dependent Degradation. EBNA4, EBNA1, and an EBNA1
deletion mutant lacking the Gly-Ala repeat were compared for
their capacity to serve as substrates for ubiquitinyproteasome-
dependent degradation in a cell-free system. Processing assays
were performed as described using in vitro-labeled substrates
and crude reticulocyte lysates or fractionated components of
the ubiquitin conjugation system. EBNA4 was degraded in an
ATP-dependent fashion as demonstrated by the disappear-
ance of the 35S-labeled polypeptide in SDSyPAGE and by the
release of TCA-soluble radioactivity (Fig. 1 A–E and Fig. 2).
The ATP-dependent effect required ubiquitin, the ubiquitin
conjugating enzymes, and the 26S complex present in fraction
II of the rabbit reticulocyte lysate (Fig. 1B). The involvement
of ubiquitination was confirmed by the accumulation of high
molecular weight EBNA4 species when the assay was per-
formed in the presence of ATP-gS and ubiquitin aldehyde to
prevent cleavage of the polyubiquitin chains by C-terminal
hydrolases (Fig. 1C). The specificity of the conjugates was
demonstrated in reconstitution assays where exogenous ubiq-
uitin and ubiquitin-conjugating enzymes were added in the
presence of ATP-gS (Fig. 1D). Finally, the ATP-dependent
effect was inhibited by addition of the peptide aldehyde
MG132, confirming that the proteasome is required for deg-
radation of the ubiquitinated EBNA4 (Fig. 1E). EBNA4 was
also degraded in an ATP-independent manner, probably due
to the presence of ATP-independent cytosolic proteases in the
crude reticulocyte lysates. The ATP-independent activity ex-
hibited a slower kinetics (data not shown) and was not
inhibited by MG132 (Fig. 1E), suggesting that the 20S pro-
teasome is not involved in this effect.
We then turned to the EBNA1 protein and found that in
vitro translated EBNA1 was resistant to ATP-dependent deg-
radation (Fig. 2 A), whereas the E1-DGA mutant that lacks the
Gly-Ala domain was degraded as efficiently as EBNA4 (Fig.
2B). Ten to 18% specific degradation of the E1-DGA polypep-
tides was demonstrated by monitoring the release of TCA-
soluble radioactivity as compared with 1–2% degradation of
EBNA1. EBNA1 was also less sensitive than EBNA4 to
ATP-independent degradation whereas deletion of the Gly-
Ala domain resulted in significant degradation of the E1-DGA
polypeptide (Fig. 2C), confirming the previous observation
that the repeat may influence the sensitivity of EBNA1 to
cytosolic proteases (13).
Insertion of Gly-Ala Repeat Prevents the Ubiquitiny
Proteasome-Dependent Degradation of EBNA4 Chimeras.
The different behavior of EBNA1 and E1-DGA in the cell-free
degradation assays suggested that presence of the Gly-Ala
repeat may interfere with the ubiquitinyproteasome-
dependent processing pathway. To test this possibility and gain
some insights on the structural constrains involved in the
inhibition, we constructed EBNA4 chimeras containing repet-
itive sequences of different length or inserted in different sites
Medical Sciences: Levitskaya et al. Proc. Natl. Acad. Sci. USA 94 (1997) 12617
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of the protein (Fig. 3). In-frame insertion of the 239-amino
acid-long Gly-Ala repeats of EBNA1 into the MscI site of
EBNA4 yielded the E4-flGA chimera that was virtually in-
sensitive to ATP-dependent degradation (Fig. 4A). The flGA
sequence had similar inhibitory effect in EBNA1 and EBNA4
as judged by comparing the specific degradation of EBNA1y
E1-DGA and EBNA4yE4-flGA pairs (Table 1). Similar levels
of inhibition were also achieved by inserting a shorter cassette
encoding a 17-amino acid-long Gly-Ala polypeptide either in
the MscI site or in the N-terminal SspI site of EBNA4 (Fig. 4
A and B).
We next asked whether the inhibitory effect was dependent
on the amino acid composition of the repeats. Insertion of the
flGA cassettes in opposite orientation relative to the EBNA4
sequence resulted in the E4-PPA chimera that contains a
238-amino acid-long Pro-Ala repeat. The E4-PPA polypeptide
was degraded less efficiently than EBNA4, although the
inhibitory effect of the Pro-Ala sequence appeared to be
weaker than that induced by the Gly-Ala repeat (Fig. 4C).
Presence of the Gly-Ala Repeats Does Not Prevent Ubiquitin
Conjugation. Introduction of foreign sequences may affect the
capacity of chimeric proteins to interact with specific ubiquitin-
conjugating enzymes andyor ubiquitin protein ligases. To
investigate whether this could explain the resistance of the
EBNA4 chimeras to ubiquitinyproteasome-dependent degra-
dation, we tested the capacity of the E4-flGA and E4-
GA39(M) chimeras to serve as substrate for ubiquitination.
Processing assays were performed in the presence of ATP-gS
and ubiquitin aldehyde, and the formation of polyubiquitin
conjugates was monitored by the appearance of high molecular
weight polypeptides. The Gly-Ala-containing chimeras ap-
peared to be ubiquitinated as efficiently as the intact EBNA4
(Fig. 5). Interestingly, we consistently failed to demonstrate
ubiquitination of the EBNA1 and E1-DGA polypeptides (data
not shown). We cannot formally exclude that this may be due
to the poor sensitivity of our in vitro ubiquitination assay.
However, the different behavior of EBNA4 and E1-DGA
suggests that the proteasome-dependent degradation of E1-
DGA may not require ubiquitination.
FIG. 1. Processing of EBNA4 in a cell-free system. The 35S-labeled
EBNA4 was incubated for 2 hr at 37°C with crude reticulocyte lysate
or fractionated components of the ubiquitin conjugation pathway in
the presence (1 ATP) or absence (2 ATP) of ATP. Control samples
were kept on ice. The polypeptides were resolved by 8% SDSyPAGE
and visualized by PhosphorImager. The identity of the radiolabeled
bands was confirmed by Western blot analysis using specific reagents
(data not shown). One representative experiment out of five is shown
in the figure. (A) Degradation of EBNA4 by crude rabbit reticulocyte
lysate. (B) Reconstitution experiments demonstrating that degrada-
tion is dependent on ubiquitin (Ub), ubiquitin-conjugating enzymes,
and the 26S proteasome (Fr. II). (C) Accumulation of polyubiquiti-
nated EBNA4 in the presence of ATP-gS. (D) Identity of the
polyubiquitinated species demonstrated in reconstitution experiments
using ATP-gS and ubiquitin aldehyde (Ubal). (E) Inhibition of
ATP-dependent degradation by the proteasome inhibitor MG132.
Degradation was assessed by monitoring the release of TCA-soluble
radioactivity and percent degradation was calculated as described.
FIG. 2. Processing of EBNA1 and E1-DGA. In vitro degradation of
EBNA1 (A) and E1-DGA (B). One representative experiment out of
five. (C) Degradation of EBNA4, EBNA1, and E1-DGA as monitored
by the release of TCA-soluble radioactivity. Results are the mean 6
SE of 16 experiments.
FIG. 3. Schematic outline of the EBNA4 chimeras. Chimeric
EBNA4 proteins were generated by in-frame insertion of sequences
coding for the 239-amino acid-long Gly-Ala repeat of EBNA1 (flGA)
or a 39-amino acid-long polypeptide containing a Gly-Ala 17 mer
flanked by unique EBNA1 residues (GA39) in the MscI site [E4-flGA,
E4-GA39(M)] or SspI site [E4-GA39(S)] of EBNA4. Insertion of the
flGA cassette in the opposite orientation relative to the EBNA4
sequence yielded the E4-PPA chimera that contains a 238-amino
acid-long Pro-Ala repeat.
12618 Medical Sciences: Levitskaya et al. Proc. Natl. Acad. Sci. USA 94 (1997)
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Inf luence of the Gly-Ala Repeat on the in Vivo Turnover of
EBNA1. Finally, we asked whether presence of the Gly-Ala
repeat may influence protein turnover in vivo. A very slow
turnover of the endogenous EBNA1 was previously observed
in lymphoblastoid cell lines (LCLs), resulting in inefficient
metabolic labeling of this protein. Therefore, we turned to a
recombinant vaccinia virus system that yields high levels of
expression over a short period of time. The half life of the
EBNA1 and E1-DGA polypeptides was compared in pulse–
chase experiments using CV1 cells infected with the corre-
sponding recombinant vaccinia viruses. EBNA1 appeared to
be stable over the 20-hr observation time (Fig. 6A). In contrast,
E1-DGA was degraded in vivo with a half life of approximately
18 hr.
DISCUSSION
The majority of intracellular proteins appear to be degraded
via the ubiquitinyproteasome pathway and the antigenic prod-
ucts of this degradation are presented at the cell surface in
association with MHC class I molecules (reviewed in refs. 16
and 17). Thus, inhibition of this process is likely to have broad
consequences for both the regulation of cellular functions and
immunogenicity. In an effort to elucidate the mechanisms by
which the Gly-Ala repeat domain of EBNA1 promotes CTL
escape, we have studied the effect of the repeat on protein
degradation in a cell-free system. We report evidence suggest-
ing that the repetitive domain interferes with ubiquitiny
proteasome-dependent degradation and may thereby protect
antigenic proteins from immune recognition.
We have shown that EBNA4, a highly immunogenic EBV
product that contains several MHC class I-restricted CTL
epitopes, is a good substrate for ubiquitinyproteasome-
dependent degradation in a cell-free system (Figs. 1 and 2). Up
to 50% of an in vitro-labeled EBNA4 polypeptide was de-
FIG. 4. Sensitivity of the EBNA4 chimeras to ubiquitiny
proteasome dependent degradation. The degradation of EBNA4 was
inhibited by insertion of Gly-Ala repeats of different length (A) and
in different positions (B). A weaker inhibition was achieved by
insertion of a Pro-Ala repeat (C). Specific degradation was calculated
from the release of TCA-soluble radioactivity as described in the
legend to Fig. 1. Results are the mean 6 SD of four experiments. The
inhibitory effect of the repeat was calculated relative to the specific
degradation of EBNA4.
FIG. 5. Ubiquitination of the Gly-Ala containing EBNA4 chime-
ras. In vitro-translated EBNA4, E4-flGA, and E4-GA39(M) were
incubated for 2 hr at 37°C in crude rabbit reticulocyte lysate containing
ATP-gS and ubiquitin aldehyde. Control samples were kept on ice or
at 37°C under ATP-depleting conditions. One representative experi-
ment out of three is shown in the figure.
Table 1. Effect of the Gly-Ala repeat on the degradation of
EBNA1 and EBNA4
% specific degradation*
Exp. 1 Exp. 2 Exp. 3 Exp. 4 Mean 6 SD
EBNA1 1.0 2.1 2.0 1.5 1.6 6 0.4
E1-DGA 10.1 13.7 18.0 13.4 13.7 6 3.3
% Inhibition† 90 85 89 88 88 6 2
EBNA4 29.3 33.1 18.4 13.0 23.3 6 8.7
E4-flGA 2.4 6.3 1.2 2.2 3.1 6 2.1
% inhibition† 92 82 95 85 88 6 6
*Calculated as the difference between the % degradation detected in
the presence or absence of ATP.
†Calculated as the ratio between the % specific degradation of
Gly-Ala-containing and Gly-Ala-deleted polypeptides.
Medical Sciences: Levitskaya et al. Proc. Natl. Acad. Sci. USA 94 (1997) 12619
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graded to TCA-soluble fragments after incubation for 2 hr
with crude rabbit reticulocyte lysate. Most of the hydrolysis
was dependent on the presence of ATP (Fig. 1 A) and occurred
at a linear rate that was proportional to the amount of
reticulocyte lysate added to the assay (data not shown). The
involvement of the proteasome was confirmed by the almost
complete inhibition of ATP-dependent degradation upon
addition of the peptide aldehyde MG132 that also inhibits the
presentation of EBNA4 epitopes in fibroblasts infected with
the relevant recombinant vaccinia virus (Fig. 1E and data not
shown). Polyubiquitination appears to be required for degra-
dation of most cellular proteins by the proteasome (reviewed
in ref. 18). Accordingly, the ATP-dependent hydrolysis of
EBNA4 was inhibited in the absence of ubiquitin and ubiq-
uitin-conjugating enzymes (Fig. 1B) whereas polyubiquiti-
nated species accumulated in the presence of ubiquitin alde-
hyde that prevents the degradation of ubiquitin conjugates by
C-terminal hydrolases (Fig. 1 C and D). In line with the
previously reported incapacity of EBNA1 chimeras to present
a known CTL target epitope (6), the in vitro-translated
polypeptide was resistant to ATPyubiquitinyproteasome-
dependent degradation in the cell-free system (Fig. 2).
In agreement with our previous finding that the Gly-Ala
repeat prevents presentation of MHC class I-restricted
epitopes, we have now shown that the repeat inhibits process-
ing by the ubiquitinyproteasome pathway. Deletion of the
repeat from EBNA1 restored processing both in vitro and in
vivo (Figs. 2 and 6) whereas insertion of the repeat into EBNA4
resulted in more than 80% inhibition of ATP-dependent
hydrolysis, thus confirming that the in vitro assay may be
directly relevant to the mechanisms resulting in the production
of antigenic peptides in vivo. Equal levels of inhibition were
achieved by insertion of either the 239-amino acid-long repeat
of the B95.8 EBNA1 or a shorter repeat containing only 17
Gly-Ala residues. The capacity to act across a wide size range
is in line with the observation that the length of the repeat
varies in natural EBV isolates, giving rise to EBNA1 polypep-
tides with characteristic patterns of migration in SDSyPAGE
(19). Although the general validity of the inhibitory effect
remains to be confirmed for other antigenic proteins, it is of
note that a similar Gly-rich domain was shown to regulate the
ubiquitinyproteasome-dependent production of NF-kB from
its p105 precursor (20). Thus, while the C-terminal portion of
p105 is rapidly degraded, sequences upstream of the Gly-rich
domain are protected from degradation. We have failed to
demonstrate the production of distinct proteolytic products on
insertion of the Gly-Ala repeats in two different positions of
EBNA4. Although this may be due to the low efficiency of the
in vitro processing assay, it is also possible that Gly-rich and
Gly-Ala sequences have different effects on the ubiquitiny
proteasome pathway, perhaps because of the presence of
additional signals that direct the partial degradation of p105.
The mechanism by which the Gly-Ala repeat inhibits ubiq-
uitinyproteasome-dependent degradation still remains ob-
scure. As illustrated by the results obtained with the E4-flGA
and E4GA39(M) chimeras, presence of the repeat does not
prevent ubiquitination (Fig. 5). This does not exclude the
possibility that ubiquitination may be affected. Polyubiquitin
chains are built by conjugation of lysines at position 29, 48, and
63 of the ubiquitin molecule (21, 22). Proteasomal degradation
of several model proteins was shown to be dependent on
polyubiquitination via Lys-48 whereas Lys-63-linked ubiquitin
chains serve non proteolytic functions (reviewed in ref. 18).
The E2 enzymes involved in this conjugation were implicated
in the signal-dependent endocytosis of surface receptors (23).
Conceivably, Gly-Ala-containing proteins may be targeted by
these E2 enzymes resulting in the formation of polyubiquiti-
nated substrates that are degraded in the endosomaly
lysosomal compartment. It is noteworthy that EBNA1 is a
dominant target for EBV-specific antibody responses (12) and
rare EBNA1-specific MHC class II-restricted CTLs have also
been demonstrated (24).
It also possible that presence of the repeat may directly
interfere with binding to the 26S complex. The observation
that neither EBNA1 nor the E1-DGA polypeptide are ubiqui-
tinated in vitro whereas the latter is efficiently degraded by the
proteasome provides indirect support to this possibility. Re-
cent evidence demonstrates that Gly-Ala repeat-like domains
contribute to the stability of spider silk protein by inducing the
formation of b-sheets (25). Similar Ala-rich domains are also
found in prion proteins where they may induce protease
resistance by promoting the formation of amyloid (26–28).
Interestingly, the intact EBNA1 was insensitive to both ATP-
dependent and ATP-independent degradation (Fig. 2C), sug-
gesting that presence of the repeat may confer a general
resistance to proteases. On the basis of the effect of the repeat
on EBNA4, which is clearly a target for both ubiquitination and
proteasome degradation, it is tempting to speculate that
hydrophobic surfaces generated by the alignment of regularly
interspersed Ala residues may interfere with the hydrophobic
interaction between the ubiquitin chains and the S5a subunit
of the 26S protease (29). Similar hydrophobic surfaces may be
generated by the Pro-Ala repeat explaining why the E4-PPA
chimera was almost as resistant to degradation as its Gly-Ala
containing counterpart (Fig. 4C). Taken together, these find-
ing suggest that certain types of repeat sequences may influ-
ence the folding pattern of proteins and affect their capacity to
associate with various components of ubiquitinyproteasome
pathway, including ubiquitin conjugation enzymes andyor the
regulatory subunits of the proteasome. Clearly, a better knowl-
edge of this protein degradation system is required to dissect
the mechanism of action of the repeat and determine whether
a different branch of the cellular proteolytic machinery may be
involved in the degradation of these substrates.
We thank J. M. Middeltorp for the kind gift of the OT1x antibody.
This investigation was supported by grants from the Swedish Cancer
Society, the Petrus and Augusta Hedlunds Stiftelse, the Karolinska
Institute, Stockholm, and Therexsys Ltd. to M.G.M. The work in A.C.’s
laboratory was supported by grants from the Israeli Academy of
FIG. 6. Influence of Gly-Ala repeat on the in vivo turnover of
EBNA1. The in vivo turnover of EBNA1 and E1-DGA was monitored
in pulse–chase experiments using CV1 cells infected with the corre-
sponding recombinant vaccinia viruses. One representative experi-
ment out of three. (A and B) In vivo-labeled polypeptides were
immunoprecipitated using the OT1x mAb and resolved by SDSy
PAGE. (C) The percent degradation was calculated from densitom-
etry scans as follows: 1, intensity of the specific band at the indicated
timeyintensity of the specific band at time 0 3 100. E, EBNA1; },
E1-DGA.
12620 Medical Sciences: Levitskaya et al. Proc. Natl. Acad. Sci. USA 94 (1997)
D
ow
nl
oa
de
d 
by
 g
ue
st
 o
n 
S
ep
te
m
be
r 
13
, 2
02
1 
Science and Humanities, the Israeli Ministry of Sciences, and the
German–Israeli Foundation for Scientific Research and Development.
J.L. received an International Cancer Technology Transfer Fellowship
(ICRETT), and A.S. was partially supported by a fellowship from the
Swedish Institute. Network activities between the laboratories of
M.G.M. and A.C. are supported by the European Commission Train-
ing and Mobility of Research program on ‘‘The central role of the
ubiquitin proteasome system in regulatory processes involved in
immunological, inflammatory, endocrinological and malignant disor-
ders’’ contract no. ERBFMRXCT960026.
1. Masucci, M. G. & Ernberg, I. (1994) Trends Microbiol. 2,
125–130.
2. Steven, N. M., Leese, A. M., Annels, N. E., Lee, S. P. &
Rickinson, A. B. (1996) J. Exp. Med. 184, 1801–1813.
3. Murray, R. J., Kurilla, M. G., Brooks, J. M., Thomas, W. A.,
Rowe, M., Kieff, E. & Rickinson, A. B. (1992) J. Exp. Med. 176,
157–168.
4. Khanna, R., Burrows, S. R., Kurilla, M. G., Jacob, C. A., Misko,
I. S., Sculley, T. B., Kieff, E. & Moss, D. J. (1992) J. Exp. Med.
176, 169–176.
5. Trivedi, P., Masucci, M., Wimberg, G. & Klein, G. (1991) Int. J.
Cancer 48, 794–800.
6. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Stegerwald-
Mullen, P. M., Klein, G., Kurilla, M. G. & Masucci, M. G. (1995)
Nature (London) 375, 685–688.
7. Townsend, A., Rothbard, J., Gotch, F., Bahadur, B., Wraith, D.
& McMichael, A. (1986) Cell 44, 959–968.
8. Michalek, M. T., Grant, E. P., Gramm, C., Goldberg, A. L. &
Rock, K. L. (1993) Nature (London) 363, 552–554.
9. Rock, K. L., Gramm, C., Rothstein, L., Clark, R., Stein, R., Dick,
L. & Hwang, D. (1994) Cell 78, 761–771.
10. Cerundolo, V., Benham, A., Braund, V., Mukherjee, S., Macino,
B., Neefjes, J. & Townsend, A. (1997) Eur. J. Immunol. 27,
336–341.
11. Hershko, A. & Rose, I. (1987) Proc. Natl. Acad. Sci. USA 84,
1829–1833.
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